Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: Role of angiotensin II type 1 receptors

British Journal of Pharmacology

Volumn 154, Issue 8, 2008, Pages 1640-1648

  MacZewski M ^a   MacZewska J ^b   Duda, M ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Heart failure; Hypercholesterolaemia; Myocardial infarction; Rat; Remodelling; Sartan; Statin

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ATORVASTATIN; CHOLESTEROL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HYPERCHOLESTEROLEMIA; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; HEPTANOIC ACIDS; HYPERCHOLESTEROLEMIA; LOSARTAN; MALE; MYOCARDIAL INFARCTION; PYRROLES; RATS; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 49449091071     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.218     Document Type: Article

References (35)

1. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S et al. (2006). Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol 290: H1960-H1968.
2. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G (2001). Improvement of left ventricular remodelling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982-985.
3. de Boer RA, Pinto YM, Suurmeijer AJ, Pokharel S, Scholtens E, Humler M et al. (2003). Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 57: 434-442.
4. Endo A, Tsujita Y, Kuroda M, Tanzawa K (1979). Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 575: 266-276.
5. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M (1995). The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1254: 7-12.
6. Fujioka T, Tsujita Y (1997). Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats. Eur J Pharmacol 323: 223-228.
7. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH (2005). IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 38: 505-515.
8. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I (1999). Angiotensin II type 1A receptor knockout mice display less left ventricular remodelling and improved survival after myocardial infarction. Circulation 100: 2093-2099.
9. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T et al. (2002). Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A reductase inhibitor, attenuates left ventricular remodelling and failure after experimental myocardial infarction. Circulation 105: 868-873.
10. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN (2004). Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 109: 97-102.
11. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A et al. (2004). Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933-1939.
12. Leenen FH, Skarda V, Yuan B, White R (1999). Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am J Physiol 276: H317-H325.
13. Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D et al. (1994). Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 267: H844-H852.
14. Maczewski M, Borys M, Kacprzak P, Gdowski T, Wojciechowski D (2006). Angiotensin II AT(1) receptor density on blood platelets predicts early left ventricular remodelling in non-reperfused acute myocardial infarction in humans. Eur J Heart Fail 8: 173-178.
15. Maczewski M, Maczewska J (2006). Hypercholesterolemia exacerbates ventricular remodelling in the rat model of myocardial infarction. J Card Fail 12: 399-405.
16. Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM et al. (1993). Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 72: 1149-1162.
17. Morgan EE, Faulx MD, McElfresh TA, Kung TA, Zawaneh MS, Stanley WC et al. (2004). Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol 287: H2049-H2053.
18. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M (1999). Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100: 2131-2134.
19. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H (1997). up-regulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 95: 473-478.
20. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M (1995). Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95: 46-54.
21. Pfeffer MA, Braunwald E (1990). Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172.
22. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT et al. (1997). Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: the healing and early afterload reducing therapy trial. Circulation 95: 2643-2651.
23. Pourdjabbar A, Parker TG, Nguyen QT, Desjardins JF, Lapointe N, Tsoporis JN et al. (2005). Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodelling. Am J Physiol 288: H1997-H2005.
24. Sola S, Mir MQS, Lerakis S, Tandon N, Khan BV (2006). Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47: 332-337.
25. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK et al. (2005). Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 111: 3411-3419.
26. Strehlow K, Nickenig G, Roeling J,Wassmann S, Zolk O, Knorr A et al. (1999). AT(1) receptor regulation in salt-sensitive hypertension. Am J Physiol 277: H1701-H1707.
27. Sun Y, Weber KT (1994). Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 28: 1623-1628.
28. Sutton MG, Sharpe N (2000). Left ventricular remodelling after myocardial infarction: pathophysiology and therapy. Circulation 101: 2981-2988.
29. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H (1992). Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327: 678-684.
30. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH (1993). Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88: 2849-2861.
31. Wang TD, Wu CC, Chen WJ, Lee CM, Chen MF, Liau CS et al. (1998). Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. Am J Cardiol 81: 531-537.
32. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H et al. (2001). Inhibition of Geranylgeranylation reduces Angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of Angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59: 646-654.
33. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ (1987). Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44-51.
34. Yang BC, Phillips MI, Ambuehl PEJ, Shen LP, Mehta P, Mehta JL (1997). Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation 96: 922-926.
35. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P et al. (1998). Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18: 1433-1439.